RPG Life Sciences closes Actis Generics acquisition via pharma subsidiary

What's the deal? RPG Life SciencesDealroom has a profile for this one. Try Dealroom →' subsidiary, RPG Active PharmaDealroom has a profile for this one. Try Dealroom →, has completed its acquisition of Actis GenericsDealroom has a profile for this one. Try Dealroom →, making the target a wholly owned entity. The transaction closed on September 24, 2026. Terms were not disclosed.

Why now? The completion follows a Share Purchase Agreement executed on July 29, 2026, under which RPG Active Pharma acquired the entire stake in Actis Generics.

What's the endgame? The move expands the group's presence in the pharmaceutical sector through its specialised subsidiary. Effective from the closing date, Actis Generics Private Limited operates as a wholly owned entity under RPG Active Pharma.

RPG Life SciencesDealroom has a profile for this one. Try Dealroom → formalised the deal through a filing with the National Stock ExchangeDealroom has a profile for this one. Try Dealroom → and BSEDealroom has a profile for this one. Try Dealroom →, confirming regulatory intimation under SEBI Listing Regulations.

The signal: The acquisition ties a listed pharmaceutical parent more tightly to a specialist generics business, a common route for Indian drugmakers seeking to broaden portfolios through consolidation rather than build capacity from scratch.

Read more: scanx.trade

Image credit: Monash Public Library Service